Background
==========

Despite improvements in the early detection of gastric cancer, a significant proportion of patients present with inoperable stages where chemotherapy is required. 5-fluorouracil (5-FU) remains the main chemotherapeutic agent for the treatment of gastric cancer, and combination chemotherapy with 5-FU has shown an improved clinical outcomes \[[@B1]\]. 5-FU with cisplatin showed an effective clinical outcome \[[@B2]\], however, toxicities were considerable \[[@B1]\]. Oxaliplatin, another platinum based agent, has a more favorable tolerability profile than cisplatin. Hence, a combination chemotherapy of 5-FU with oxaliplatin has been investigated in numerous phase II studies, using different doses and schedules \[[@B3]-[@B7]\]. However it remains to be clarified which is the best combination, with the highest efficacy and lowest toxicity. Thus, we conducted a phase II trial of 5-FU, folinic acid and oxaliplatin (a modified FOLFOX-6 regimen) in advanced gastric cancer (AGC) patients as a first line palliative chemotherapy.

Another problem in chemotherapy of AGC is the selection of patients who might benefit from specific chemotherapy. One promising therapeutic challenge is to identify genetic markers based on pharmacogenomics. Genomic polymorphism can influence drug transport, metabolism and cellular response, and lead to individual variations in terms of the response and toxicity and even to overall survival \[[@B8],[@B9]\]. A number of studies have investigated the relationships between treatment outcomes and individual genetic polymorphisms which will determine the efficacies and toxicities of chemotherapeutic agents, especially of 5-FU and platinum agents.

The antitumor effect of 5-FU has ascribed to the competitive inhibition of thymidylate synthase (TS) \[[@B10]\]. A high intratumoral TS expression has been correlated with resistance to 5-FU and a poor clinical outcome in colorectal cancer \[[@B11]-[@B14]\]. Several polymorphisms in TS may influence TS mRNA transcription, stability, or protein expression. Polymorphisms with double or triple repeats of a 28-base pair (bp) sequence in the enhancer region (ER) are known to be associated with the efficacy and toxicity of 5-FU \[[@B15]-[@B17]\]. The -6 bp/-6 bp deletion polymorphism in the 3\'UTR of TS is associated with decreased mRNA stability in vitro and lower intratumoral TS expression *in vivo*. Further, the 6 bp polymorphism varies greatly within different ethnic populations and is in linkage disequilibrium with the TS 5\' tandem repeat enhancer polymorphism \[[@B18]\]. A functional G/C single nucleotide polymorphism (SNP) within a second repeat of triple repeat (3R) allele was found to determine two additional alleles (3G or 3C) at this locus \[[@B19]\]. *In vitro*, the 3G containing genotype showed a higher TS mRNA expression \[[@B19],[@B20]\].

Oxaliplatin has antitumor activity by virtue of its ability to form platinum-DNA adducts. Bulky platinum-DNA adducts are mainly repaired by the nucleotide excision repair pathway, in which proteins of the excision repair cross-complementation 1 (ERCC1), xeroderma pigmentosum group D (XPD, also known as ERCC2) and X-ray repair cross-complementing group (XRCC), have important roles \[[@B13],[@B21]\]. ERCC, XPD and XRCC contain SNPs that may confer different activities to platinum agents, thus modifying the clinical outcome \[[@B22]-[@B24]\]. Glutathione S- transferase π 1 (GSTP1), which is involved in platinum detoxification, also has a polymorphism that is associated with prolonged survival in cisplatin-treated gastric cancer \[[@B25],[@B26]\].

The primary endpoint of this study was to evaluate the efficacy in terms of response rate and the secondary endpoints of this study were to evaluate the efficacy in terms of time to progression, overall survival and toxicity of modified FOLFOX-6 chemotherapy in AGC patients. Exploratory pharmacogenomic collateral study was performed to identify the predictive or prognostic value of germline polymorphisms of candidate genes associated with 5-FU and oxaliplatin.

Methods
=======

Patients
--------

Patients with metastatic or relapsed AGC were enrolled in this prospective phase II clinical trial. Patients were administered a modified FOLFOX-6 regimen composed of a 2 hours infusion of oxaliplatin (100 mg/m^2^) and folinic acid (100 mg/m^2^), followed by a 46 hour continuous infusion of 5-FU (2,400 mg/m^2^), as a first-line palliative chemotherapy. Treatment was repeated every 2 weeks until disease progression, patient refusal or unacceptable adverse reactions.

Eligibility criteria included: 1) pathologically confirmed gastric adenocarcinoma with a bi-dimensionally measurable lesion; 2) no prior chemotherapy except adjuvant chemotherapy administered more than 6 months previously; 3) ECOG performance 0--2; 4) adequate bone marrow, hepatic, and renal functions. ECOG performance status \[[@B27]\] defined as follows: ECOG 0-fully active, able to carry on all pre-disease performance without restriction; ECOG 1-restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; ECOG 2 -- ambulatory and capable of all self care but unable to carry out any work activities; ECOG3 -- capable of only limited self care, confined to bed or chair more than 50% of waking hours; ECOG 4 -- completely disabled.

Patients received a blood test for toxicity every cycle and were re-evaluated every 3 cycles by abdominal computed tomography. The tumor responses were evaluated using WHO criteria \[[@B28]\] and all responses were confirmed at least 4 weeks after initial assessment. Toxicity was graded according to National Cancer Institute common terminology criteria for adverse events (CTCAE version 3.0). Peripheral sensory neuropathy was also graded according to same toxicity criteria. In the event of toxicity, dose modification and treatment delays were performed according to the protocol. Dose modification of oxaliplatin to 85 mg/m^2^was planned if the patient experienced grade 2 or 3 sensory neuropathy and we strictly followed the protocol which permitted the initiation of chemotherapy after recovery from all toxicities less than grade 2.

Genotyping
----------

To evaluate the clinical usefulness of germline genotyping, we analyzed peripheral blood samples that were obtained from patients with informed consent. Genomic DNA was extracted from peripheral blood samples using QIAmp DNA blood kits (Qiagen Inc, Valencia, CA, USA), and each polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism methods. Table [1](#T1){ref-type="table"} summarizes the primer sequences, the restriction enzymes used \[[@B15],[@B16],[@B19],[@B29]-[@B34]\]. The polymorphisms investigated included TS (28-bp repeat in enhancer region \[[@B16]\], G/C SNP in the 3R allele \[[@B19]\], a 6-bp deletion in 3\'UTR \[[@B15]\]), GSTP1 (Ile105Val \[[@B29]\]), ERCC1 (Asn118Asn \[[@B30]\], C8092A \[[@B31]\]), XPD (Arg156Arg \[[@B32]\], Asp312Asn \[[@B33]\], Lys751Gln \[[@B33]\]), and XRCC (Arg399Gln \[[@B34]\]).

###### 

Primer sequences and restriction enzymes

  Gene                 Polymorphisms                   Location      Primer                                        Restriction enzyme   References
  -------------------- ------------------------------- ------------- --------------------------------------------- -------------------- ------------
  TS (Ch 18p11.32)     2R or 3R VNTR in ER\*           ER (5\'UTR)   Forward: GTGGCTCCTGCGTTTCCCCC                                      16
                                                                     Backward: GCTCCGAGCCGGCCACAGGCATGGCGCGG                            
                       G/C SNP in 3R                   5\'UTR        Forward:: GTGGCTCCTGCGTTTCCCCC                Hae III              19
                                                                     Backward: GCTCCGAGCCGGCCACAGGCATGGCGCGG                            
                       6 bp insertion(+)/deletion(-)   3\'UTR        Forward: CAAATCTGAGGGAGCTGAGT                 Dra I                15
                                                                     Backward: CAGATAAGTGGCAGTACAGA                                     
  GSTP1 (Ch.11q13)     A/G, Ile105Val                  Exon5         Forward: CTCTATGGGAAGGACCAGCA                 BsmA I               29
                                                                     Backward: TGAGGGCACAAGAAGCCCCT                                     
  ERCC1 (Ch.19q13.2)   C/T, Asn118Asn                  Exon4         Forward: TCATCCCTATTGATGGCTTCTGCCC            BsrD I               30
                                                                     Backward: GACCATGCCCAGAGGCTTCTCATAG                                
                       C8092A                          3\'UTR        Forward: CAGAGACAGTGCCCCAAGAG                 Mbo II               31
                                                                     Backward: GGGCACCTTCAGCTTTCTTT                                     
  XPD (Ch.19q13.3)     C/A, Arg156Arg                  Exon6         Forward: CACACCTGGCTCATTTTTGTAT               Tfi I                32
                                                                     Backward: TCATCCAGGTTGTAGATGCCA                                    
                       G/A, Asp312Asn                  Exon10        Forward: CTGTTGGTGGGTGCCCGTATCTGTTGGTCT       Sty I                33
                                                                     Backward: (TAATA)TCGGGGCTCACCCTGCAGCACTTCCT                        
                       A/C, Lys751Gln                  Exon23        Forward: GCCCGCTCTGGATTATACG                  Pst I                33
                                                                     Backward: CTATCATCTCCTGGCCCCC                                      
  XRCC (Ch.19q13.2)    G/A, Arg399Gln                  Exon10        Forward: TTGTGCTTTCTCTGTGTCCA                 Msp I                34
                                                                     Backward: TCCTCCAGCCTTTTCTGATA                                     

Ch, chromosome; VNTR, variable number tandem repeats; UTR, untranslated region; ER, enhancer region; TS, thymidylate synthase; GSTP, glutathione S- transferase π; ERCC1, excision repair cross-complementation 1; XPD, xeroderma pigmentosum group D; XRCC, X-ray repair cross-complementing group.

\*VNTR polymorphism is a double repeat (2R) or triple repeat (3R) of 28-bp sequence in TS 5\'UTR.

The study protocol was reviewed and approved by the institutional review board of Seoul National University Hospital.

Statistical analyses
--------------------

A single-stage design by A\'Hern is chosen for definition of the total number of patients required for the phase II study \[[@B35]\]. We set response rate of 35% as the target activity level \[[@B6]\] and chose 20% as the lowest response rate. Our study is designed to have 90% power to accept the hypothesis and 5% significance to reject the hypothesis. In this phase II study, at least 73 evaluable patients will be required to be enrolled. Associations between response rate and polymorphism were assessed by a Chi-square test and Fisher\'s exact test, where appropriate. To verify allelic frequencies, a Chi-square test was used to confirm agreement with the Hardy-Weinberg equilibrium. Time to progression (TTP) was defined as the interval between the initiation of treatment and the date when disease progression was first documented, or the date of death from any cause. Overall survival (OS) was measured from the date of treatment initiation to the date of death. Median TTP and OS according to prognostic factors were calculated using the Kaplan-Meier method. Multivariate analyses were carried out using Cox proportional hazard regression models for TTP and OS. All values were two sided and statistical significance was accepted at the *p*\< 0.05 level. SPSS version 12.0 software (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses.

Cell culture and 5-FU sensitivity
---------------------------------

Seven human gastric cancer cell lines (SNU 1, 5, 16, 484, 601, 620 and 638, obtained from the Korean Cell Line Bank, Seoul, Korea) were examined. Genotypes of each cell line were determined by same methods as described above. Equal numbers of cells harvested during the exponential growth phase were plated in 100 μl per well with various concentrations (0.1 nM to 50 μM, diluted in semilog fashion) for 72 hours. The growth inhibition was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (MTT test; Sigma, St Louis, MO, USA) and the concentrations required to inhibit cell growth by 50% (IC~50~) were calculated.

Western blot
------------

TS protein expressions were determined by Western immunoblotting, as previously described \[[@B36]\]. Equivalent amounts of protein were processed by 12% SDS-PAGE, and electroblotted on to Hybond ECL nitrocellulose membranes, which were blocked overnight using blocking buffer, and then incubated with primary antibody against human TS (monoclonal mouse anti-TS antibody 1:1000 dilution in blocking buffer; TS Ab-1, clone TS106, Neomarkers). Proteins were detected by enhanced chemiluminescence. For the semiquantitative analysis of Western blots, subsaturated autoradiograms were scanned and signals were analyzed by densitometry (TINA 2.09 software; Raytest, Straubenhardt, Germany).

Results
=======

Patient characteristics and clinical outcomes
---------------------------------------------

Eighty patients were included in this trial and 7 patients were lost to follow up. A total of 73 patients, composed of 48 men and 25 women, with a median age of 59 years (range: 24--77) were finally evaluated in the study which ran from March 2003 to March 2005. The clinical characteristics of patients are summarized in Table [2](#T2){ref-type="table"}. During a median follow-up of 21.2 months, 42 death events and 68 progression events occurred. A total of 470 cycles of modified FOLFOX-6 were delivered with a median number of 6 cycles per patient (range, one to 12). Dose intensity level was 83.2%. The median cumulative dose for oxaliplatin was 570 mg/m^2^. The overall response rate (RR) was 43.8% (Table [3](#T3){ref-type="table"}). The median TTP and OS were 6.0 months (95% CI, 4.8--7.2 months) and 12.6 months (95% CI, 8.7--16.5 months), respectively. Only performance status was found to be a statistically significant prognostic factor for TTP (6.3 months in ECOG 0--1 *vs*. 3.7 months in ECOG 2, *p*= 0.037). RR, TTP and OS were not different according to histotype (diffuse *vs*. intestinal type). Otherwise no significant association was observed between patient characteristics and clinical outcomes.

###### 

Patient characteristics

  Characteristics         No. of Pts (N = 73)   \%
  ----------------------- --------------------- ------
  Sex                                           
   Male                   48                    65.8
   Female                 25                    34.2
  Age, years                                    
   median                 59                    
   range                  24--77                
  Performance status                            
   ECOG 0--1              60                    82.2
   ECOG 2                 13                    17.8
  Histopathologic type                          
   Intestinal type        47                    64.4
   Diffuse type           23                    31.5
   Unknown                3                     4.1
  Disease status                                
   Relapsed               19                    26.0
   Initial stage IV       54                    74.0
  Metastatic site                               
   Liver                  30                    41.1
   Peritoneum             29                    39.7
   LN (distant M1 node)   23                    31.5
   Others                 18                    24.7

ECOG, eastern cooperative oncology group; LN, lymph node.

###### 

Results of modified FOLFOX-6 chemotherapy

  Response              No. of Pts (%)
  --------------------- ----------------
  Complete response     0 (0.0)
  Partial response      32 (43.8)
  Stable disease        21 (28.8)
  Progressive disease   20 (27.4)

Toxicities
----------

Severe hematologic toxicities were uncommon (Table [4](#T4){ref-type="table"}). The main grade 3 and 4 toxicity (per patients) was neutropenia (11.0%). Non-hematologic toxicities were mild and 1.4% experienced grade 3 peripheral neuropathy. No febrile neutropenia was observed. Toxicities were generally brief, reversible and manageable.

###### 

Toxicities according to National Cancer Institute CTCAE (per patient)

  Toxicities             Grade 1--2   Grade 3--4       
  ---------------------- ------------ ------------ --- ------
  Hematologic                                          
   Leucopenia            13           17.8         0   0.0
   Neutropenia           10           13.7         8   11.0
   Anemia                12           16.4         0   0.0
   Thrombocytopenia      5            6.8          1   1.4
  Non-hematologic                                      
   Neuropathy            12           16.4         1   1.4
   AST/ALT abnormality   3            4.1          0   0.0
   Nausea                19           26.0         0   0.0
   Vomiting              9            12.4         0   0.0
   Mucositis             1            1.4          1   1.4

AST, Aspartate aminotransferase; ALT, Alanine aminotransferase.

Correlation between genotypes and response rates
------------------------------------------------

We analyzed 10 germline polymorphisms within 5 genes. All observed genotype frequencies were in agreement with the Hardy-Weinberg equilibrium. The genotype distributions of -6 bp/-6 bp, +6 bp/-6 bp and +6 bp/+6 bp were observed in 40 (54.8%), 30 (41.1%) and 3 (4.1%), respectively. The frequencies of 3G containing genotype and non-3G containing genotype were 69.9% and 28.8%, respectively. Table [5](#T5){ref-type="table"} compares RR and polymorphisms. RR was significantly higher in patients with a -6 bp/-6 bp homozygote in TS-3\'UTR (55.0% *vs*. 30.3% in +6 bp/+6 bp or +6 bp/-6 bp, *p*= 0.034). There was no difference in RR according to TS enhancer region polymorphism (47.1% in 3G containing genotype *vs*. 33.3% in non-3G containing genotype, *p*= 0.285). In XPD Arg156Arg, a higher RR was observed in C/A or A/A genotypes compared with the C/C genotype (52.0% *vs*. 26.1%, *p*= 0.038). The other polymorphisms were not found to be significantly associated with RR. No association was observed between polymorphisms and toxicities (data not shown).

###### 

Response rate according to the clinical factors and the genotypes

                                                     Overall frequency   Responder               
  ---------------------------- --------------------- ------------------- ----------- ---- ------ -------
  Age                          ≤ 55                  31                  42.5        15   48.4   0.501
                               \> 55                 42                  57.5        17   40.5   
  Performance                  ECOG 0--1             60                  82.2        28   46.7   0.295
                               ECOG 2                13                  17.8        4    30.8   
  Histotype                    Intestinal            47                  67.1        19   40.4   0.557
                               Diffuse               23                  32.9        11   47.8   
                               unknown               3                                           
  Disease status               Initial stage IV      54                  74.0        27   50.0   0.107
                               Relapsed              19                  26.0        5    26.3   
  TS in 5\'UTR^*\#*^           2R/2R, 2R/3C, 3C/3C   21                  28.8        7    33.3   0.285
                               2R/3G, 3C/3G, 3G/3G   51                  69.9        24   47.1   
                               unknown               1                   1.4                     
  TS 6-bp deletion in 3\'UTR   -6/-6                 40                  54.8        22   55.0   0.034
                               +6/+6 or +6/-6        33                  45.2        10   30.3   
  GSTP1-Ile105Val (A105G)      A/A                   44                  60.3        22   50.0   0.191
                               A/G or G/G            29                  39.7        10   34.5   
  ERCC-Asn118Asn               C/C                   40                  54.8        17   42.5   0.800
                               C/T or T/T            33                  45.2        15   57.5   
  ERCC-C8092A                  C/C                   44                  60.3        18   40.9   0.535
                               C/A or A/A            29                  39.7        14   48.3   
  XPD- Arg156Arg               C/C                   23                  31.5        6    26.1   0.038
                               C/A or A/A            50                  54.0        26   52.0   
  XPD-Asp312Asn                G/G                   8                   11.0        1    12.5   0.072
                               G/A                   65                  89.0        31   47.7   
  XPD-Lys751Gln                A/A                   62                  84.9        28   45.2   0.746
                               A/C or C/C            11                  15.1        4    36.4   
  XRCC1-Arg399Gln              G/G                   48                  65.8        21   43.8   0.984
                               G/A or A/A            25                  34.2        11   44.0   

RR, response rate.

\**p*-value for the comparison between response rate and genotypes, based on Pearson\'s χ 2 test (using Fisher\'s exact test, if N ≤ 5).

^\#^Analysis of the TS-5\'UTR VNTR polymorphism with G/C SNP change in 3R allele carriers.

Time to progression, overall survival, and the correlation with genotype
------------------------------------------------------------------------

Among the polymorphisms investigated, only the 6-bp deletion homozygote (-6 bp/-6 bp) in TS-3\'UTR was found to be significantly associated with a favorable TTP and OS. The TTP of patients with -6 bp/-6 bp in TS-3\'UTR was 6.3 months, whereas that of patients with +6 bp/+6 bp or +6 bp/-6 bp was 4.7 months (*p*= 0.014, *p*-value based on log rank test), and a significant difference was also observed between these genotypes in terms of OS (17.8 months in -6 bp/-6 bp *vs*. 10.3 months in +6 bp/+6 bp or +6 bp/-6 bp, *p*= 0.032, *p*-value based on log rank test). In Figure [1](#F1){ref-type="fig"} Kaplan-Meier plots are shown and reveal the relationship between TTP and OS according to the TS-3\'UTR polymorphism. In addition, a prolonged TTP was observed in the C/A or A/A genotype of XPD Arg156Arg (6.2 months *vs*. 4.1 months in C/C, *p*= 0.022). However, no association was observed for the other polymorphisms and TTP or OS (Table [6](#T6){ref-type="table"}). Variables showing association with TTP in univariate analysis with *p*\< 0.10 (6-bp deletion in TS-3\'UTR, XPD- Arg156Arg, XPD-Asp312Asn, performance status) were included for multivariate analysis using Cox proportional hazard regression models. In multivariate analysis, TS-3\'UTR was identified as an independent prognostic marker of survival (Table [7](#T7){ref-type="table"}). The 6-bp deletion in TS-3\'UTR was independently associated with a prolonged TTP. (Hazard Ratio \[HR\] = 0.561).

![**Kaplan-Meier plots of TTP and OS, according to 6-bp deletion polymorphism in 3\'UTR of TS.** The 6-bp deletion homozygote (-6 bp/-6 bp) was significantly associated with prolonged TTP (6.3 months *vs*. 4.7 months in +6 bp/+6 bp or +6 bp/-6 bp, *p*= 0.014) and OS (17.8 months vs. 10.3 months in +6 bp/+6 bp or +6 bp/-6 bp, *p*= 0.032).](1471-2407-8-148-1){#F1}

###### 

Comparison of TTP and OS according to the clinical factors and genotypes

                                                     Time to progression   Overall survival                                                               
  ---------------------------- --------------------- --------------------- ------------------ -------------- ------- ------------- ------- -------------- -------
  Age                          ≤ 55                  5.6                   1.000                             0.485   11.9          1.000                  0.146
                               \> 55                 5.0                   0.840              0.514--1.371           10.8          1.610   0.847--3.060   
  Performance                  ECOG 0--1             6.0                   1.000                             0.042   12.6          1.000                  0.124
                               ECOG 2                3.7                   1.892              1.022--3.501           10.0          1.722   0.862--3.441   
  Histotype                    Intestinal            6.1                   1.000                             0.495   14.5          1.000                  0.392
                               Diffuse               5.6                   1.197              0.714--2.009           10.8          1.337   0.687--2.602   
  Disease status               Initial stage IV      5.6                   1.000                             0.362   12.6          1.000                  0.903
                               Relapsed              6.0                   1.288              0.748--2.219           10.8          0.959   0.489--1.881   
  TS 5\'UTR                    2R/2R, 2R/3C, 3C/3C   5.6                   1.000                             0.781   10.8          1.000                  0.244
                               2R/3G, 3C/3G, 3G/3G   6.1                   0.781              0.415--1.470           17.4          0.669   0.340--1.316   
  TS 6-bp deletion in 3\'UTR   +6/+6 or +6/-6        4.7                   1.000                             0.033   10.3          1.000                  0.046
                               -6/-6                 6.3                   0.572              0.342--0.956           17.8          0.536   0.291--0.988   
  GSTP1-Ile105Val              A/A                   6.0                   1.000                             0.398   11.9          1.000                  0.621
                               A/G or G/G            6.3                   1.243              0.750--2.061           14.5          0.621   0.452--1.606   
  ERCC-Asn118Asn               C/C                   6.2                   1.000                             0.433   14.5          1.000                  0.472
                               C/T or T/T            5.0                   0.822              0.503--1.342           11.9          1.251   0.680--2.302   
  ERCC-C8092A                  C/C                   6.1                   1.000                             0.826   17.8          1.000                  0.326
                               C/A or A/A            5.6                   0.945              0.569--1.568           11.4          1.356   0.739--2.490   
  XPD- Arg156Arg               C/C                   4.1                   1.000                             0.022   10.5          1.000                  0.355
                               C/A or A/A            6.2                   0.533              0.311--0.913           14.5          0.738   0.367--1.405   
  XPD-Asp312Asn                G/G                   6.1                   1.000                             0.084   14.0          1.000                  0.673
                               G/A                   3.5                   1.942              0.914--4.129           10.8          0.800   0.283--2.256   
  XPD-Lys751Gln                A/A                   6.1                   1.000                             0.693   12.6          1.000                  0.173
                               A/C or C/C            4.6                   0.872              0.440--1.725           Not reached   0.488   0.174--1.369   
  XRCC1-Arg399Gln              G/G                   6.1                   1.000                             0.744   15.3          1.000                  0.160
                               G/A or A/A            5.9                   1.090              0.649--1.832           10.3          1.575   0.835--2.971   

Mo, months; HR, hazard ratio; CI, confidence interval.

\* By Kaplan-Meier analysis

^\#^By Cox proportional hazard regression model, adjusted for performance

Note: If the hazard ratio is greater than 1, the hazard ratio can be thought of as the average increased risk of progression, or death at any point in time, compared with the reference group (described above line).

###### 

Clinical factors and genotypes influencing survival in multivariate analyses

                                    TTP                    OS                             
  --------------------------------- ---------------------- ------- ---------------------- -------
  TS 6-bp deletion in 3\'UTR        0.561 (0.331--0.950)   0.032   0.553 (0.285--1.072)   0.079
  XPD-Arg156Arg                     0.705 (0.407--1.220)   0.210   0.923 (0.456--1.867)   0.823
  XPD-Asp312Asn                     1.956 (0.902--4.240)   0.089   0.802 (0.281--2.286)   0.679
  Performance (ECOG 0--1 *vs*. 2)   1.973 (1.034--3.762)   0.073   1.638 (0.816--3.288)   0.165

Correlations between in vitro data and the TS polymorphism
----------------------------------------------------------

The above clinical result led to further investigation for theoretical confirmation in *in vitro*condition. Using seven human gastric cancer cell lines and Western blotting, we investigate for correlations between genotypes, protein expressions, and 5-FU sensitivities. Two out of seven cell lines (SNU 601, 620) had -6 bp/-6 bp homozygotes polymorphism in TS 3\'UTR. Six bp deletion homozygotes tended to show lower TS protein expression (TS/tubulin expression ratio 0.88 in -6 bp/-6 bp *vs*. 1.15 in +6 bp/+6 bp or +6 bp/-6 bp, *p*= 0.095 by Mann-Whitney U test). Subsequent Western blot analysis showed lower TS expression was associated with higher sensitivity to 5-FU in our *in vitro*data \[[@B36]\]. Linear regression analysis revealed a statistically significant correlation between TS protein expression and the IC~50~of 5-FU (*p*= 0.002, r^2^= 0.887), and the 6-bp deletion polymorphism in TS-3\'UTR was associated with lower TS expression and more sensitivity to 5-FU in gastric cancer cell lines *in vitro*.

Discussion
==========

In this work we evaluated the efficacy of modified FOLFOX-6 chemotherapy in AGC patients, and examined the relevance of the relationship between germline genetic polymorphisms and the clinical outcome. The results indicate that a modified FOLFOX-6 chemotherapy appears to be active and well tolerated.

With an overall RR of 43.8%, our results compare favorably with other phase II studies of FOLFOX chemotherapy, which range from 38% to 56% \[[@B3]-[@B7]\]. By contrast to the FOLFOX-6 regimen for AGC \[[@B3]\], the regimen here omitted the 5-FU bolus injection in order to reduce myelosuppression. In terms of toxicities, the modified FOLFOX-6 regimen showed an 11.0% occurrence of grade 3 or 4 neutropenia, which is lower than the 38% level shown with the FOLFOX-6 regimen \[[@B3]\]. Grade 3 or 4 peripheral sensory neuropathy occurred in only 1.4% of the patients. This was lower than original FOLFOX-6 using oxaliplatin of 100 mg/m^2^with a median cumulative dose of 901 mg/m^2^for oxaliplatin. In our study the median cumulative dose of 570 mg/m^2^for oxaliplatin which is lower than original FOLFOX-6. With considering median cumulative dose of oxaliplatin, this was comparable to other lower dose oxaliplatin-based regimen or omitting the 5-FU bolus \[[@B4],[@B7]\]. In our study, dose modification of oxaliplatin to 85 mg/m^2^was performed if the patient experienced grade 2 peripheral neuropathy and we strictly followed the protocol which permitted the initiation of chemotherapy after recovery from all toxicities less than grade 2.

In the present study, TS and XPD polymorphisms were found to be associated with RR, and these polymorphisms could be used as predictive markers. TS, the target of 5-FU, has been investigated repeatedly in various aspects to predict the response to 5-FU, in terms of polymorphism, mRNA and protein expressions \[[@B10],[@B16]\]. In our study, the 6-bp deletion polymorphism in TS-3\'UTR was found to be correlated with favorable clinical outcome. That means that the patients with -6 bp/-6 bp were found to have a higher RR and prolonged time to progression. TS-3\'UTR plays a role as a post transcriptional regulator, mainly by controlling mRNA stability and/or translational efficiency. The 6-bp deletion in TS-3\'UTR reduces mRNA stability and lowers intratumoral TS mRNA levels \[[@B18]\]. A reduced level of TS mRNA might also lead to a lower TS protein expression, and make tumors more sensitive to 5-FU based chemotherapy \[[@B13],[@B36],[@B37]\]. Previous studies in colorectal cancer provide strong evidence that a lower TS expression appears to be associated with a higher RR and prolonged survival with 5-FU based chemotherapy \[[@B11],[@B13],[@B14]\]. These findings are supported by *in vitro*data that -6 bp/-6 bp in TS-3\'UTR affect to lower TS expression and higher sensitivity to 5-FU in gastric cancer cell lines. In gastric cancer, we confirmed that a 6-bp deletion is associated with better clinical outcome in homogenous patients treated with a first line modified FOLFOX-6 regimen.

However, some studies conducted in Western countries \[[@B25],[@B26]\] failed to find a correlation between the 6-bp deletion polymorphism and 5-FU sensitivity in gastric cancer, while our results are concordant with those of another study conducted in an Asian \[[@B38]\]. One possible explanation for this contradictory result is ethnic difference.

Caucasian patients had higher proportion of favorable 2R/2R genotype (16.0% to 26.4%) \[[@B26],[@B39],[@B40]\], lower proportion of unfavorable 3R/3R or 3G containing genotypes in 5\'UTR (28.8% to 39.2%) \[[@B26],[@B34],[@B40]\] and lower proportion of favorable -6 bp/-6 bp in 3\'UTR (7.8% to 22.0%) \[[@B18],[@B26],[@B34],[@B40]\]. In contrast, Asian patients showed lower proportion of favorable 2R/2R (0.0% to 6.0%) \[[@B34],[@B41]\] higher proportion of unfavorable 3R/3R (66.4% to 72.3%) \[[@B34],[@B42]\] and higher proportion of favorable -6 bp/-6 bp (36.4% to 56.0%) \[[@B18],[@B34],[@B38]\]. These differences between favorable and unfavorable genotype frequencies might make different results according to ethnic diversity.

The clinical influence of TS polymorphism in 5-FU based chemotherapy are often controversial because of different clinical settings (adjuvant *vs*. palliative), tumor type (colon *vs*. gastric cancer), and different 5-FU infusion times \[[@B16],[@B25],[@B26],[@B39],[@B42]-[@B45]\]. These experimental variables should be considered when interpreting predictive values of the TS polymorphism.

Another factor to be taken into consideration is the possible impact on outcome of other drugs combined with 5-FU. Even antitumor activity of 5-FU may be decreased by TS polymorphism, another combined drug might compensate the decreased antitumor activity and make sufficient tumor response. This would make the meaningful polymorphism in single agent protocol less significant in combination regimens \[[@B46]\]. Thus this could account for the differing results with prior reports. A meta-analysis could perhaps provide some clarity in this area.

XPD (also known as ERCC2) encodes DNA helicase, which is a member of the nuclear excision repair pathway and plays a role in repairing platinum-DNA adducts. The C/C genotype of XPD-Arg156Arg SNP showed lower RR than C/A or A/A genotype (26.1% *vs*. 52.0%, *p*= 0.038) and shorter TTP (4.1 months *vs*. 6.2 months, *p*= 0.022). The lower RR with a modified FOLFOX-6 chemotherapy might result from the tendency that the C/C genotype of XPD- Arg156Arg had a higher DNA repair capacity than C/A or A/A genotype \[[@B32]\]. However, it did not affect to prolongation of survival. The other polymorphisms examined failed to show any relation with clinical outcome.

In the presented study, we analyzed germline genotype. Hence the correlation between germline genotype from peripheral blood and somatic genotype from tumor tissues should be considered. Few studies focused on comparing both genotypes. In terms of 28-bp repeat polymorphism, tumor specific loss of heterozygosity at the TS locus has been reported \[[@B47]\]. In contrast, some studies have reported that there is no difference in TS ER polymorphism between genotypes of tumor and normal tissues in gastric \[[@B41]\] and colorectal cancer \[[@B40]\].

Herein, we presume that germline genotypes are nearly identical to somatic genotypes, even though it might not always reflect the tumor genotype. However, germline genotypes determined from peripheral blood mononuclear cells have many strong points. The germline genotypes offer the better clinical accessibility and applicability, compared to tumor tissue DNA or mRNA, which present difficulties in obtaining and handling samples. In our results, germline genotypes, which were obtained by simple blood test, have shown a good association with the clinical outcome and are easily interpreted. In this phase II study, the small sample size (n = 73) might remains a limitation to clarify the role of polymorphism. However, our patient population was considerably homogeneous in terms of ethnicity and chemotherapeutic regimen, and this protocol was prospective.

Conclusion
==========

We found that modified FOLFOX-6 chemotherapy appears to be effective. A 6-bp deletion homozygote of TS-3\'UTR was found to be a predictive marker of the response and was also found to be associated with a prolonged TTP in AGC patients on modified FOLFOX-6 chemotherapy. Moreover, our results suggest that germline genetic polymorphisms of TS and XPD may be useful candidates for a pharmacogenomic prediction of the response to modified FOLFOX-6 chemotherapy in AGC. Alternative treatment other than 5-FU or platinum based therapy should be considered for the patients who have unfavorable genotype. We conclude that testing for the TS-3\'UTR 6-bp deletion and XPD polymorphisms might be a candidate pharmacogenomic factors to be explored in the future larger scale study to identify the gastric cancer patients who might benefit from 5-FU based first line chemotherapy.
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